Aug 5, 2026 06:00AM
Jul 9, 2026 06:01AM
Jul 9, 2026 06:00AM
Jun 29, 2026 06:01AM
Jun 29, 2026 06:00AM
Jun 23, 2026 03:48PM
Jun 23, 2026 06:01AM NCCN adds Natera's Signatera to bladder cancer treatment guidelines
Jun 23, 2026 06:00AM
May 29, 2026 06:03AM
May 29, 2026 06:00AM
May 21, 2026 07:00AM
May 21, 2026 07:00AM
May 15, 2026 12:55PM
May 15, 2026 12:45PM Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)
May 15, 2026 12:32PM
Feb 27, 2026 10:05AM
Feb 2, 2026 06:01AM
Feb 2, 2026 06:00AM
Nov 6, 2025 04:05PM
Oct 28, 2025 07:01AM
Oct 28, 2025 07:00AM Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity
Oct 20, 2025 01:05AM
Aug 19, 2025 09:22AM
Aug 18, 2025 06:01AM
Aug 18, 2025 06:00AM
Aug 7, 2025 04:05PM
May 8, 2025 04:05PM
Feb 27, 2025 04:05PM Natera Reports Fourth Quarter and Full Year 2024 Financial Results
Jan 15, 2025 07:00AM
Dec 2, 2024 08:00AM
Nov 30, 2024 04:00AM
Nov 25, 2024 09:00AM
Nov 12, 2024 04:05PM
Aug 8, 2024 04:05PM
May 14, 2024 09:00PM NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
May 9, 2024 04:05PM
May 1, 2024 07:00AM
Apr 11, 2024 08:00AM
Apr 5, 2024 07:00AM
Apr 5, 2024 07:00AM
Apr 1, 2024 08:07AM
Apr 1, 2024 08:00AM Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
Mar 14, 2024 08:00AM
Mar 7, 2024 08:06AM
Mar 7, 2024 08:00AM
Feb 28, 2024 04:05PM
Jan 30, 2024 09:15AM
Nov 8, 2023 04:05PM
Nov 2, 2023 08:32AM Natera's (NTRA) Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight in Chronic Kidney Disease
Nov 2, 2023 08:30AM

327,953 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All